Meitheal partners with Chinese company for US licencing of insulin biosimilars
The licence grants Meitheal marketing rights for insulin aspart, lispro, and glargine following FDA approval.
The licence grants Meitheal marketing rights for insulin aspart, lispro, and glargine following FDA approval.
What's Your Reaction?
